Skip to main content

Table 1 Genotype frequencies by clinicopathological variable

From: Relationships between the ABO blood group SNP rs505922 and breast cancer phenotypes: a genotype-phenotype correlation study

N = 629

CC

CT

TT

P-value

Age

   

P = 0.393

<40 years

4 (12%)

11 (32%)

19 (56%)

 

40-49 years

12 (9%)

59 (46%)

57 (45%)

 

≥50 years

62 (13%)

211 (45%)

194 (42%)

 

Tumor Stage

   

P = 0.143

I

49 (15%)

147 (44%)

137 (41%)

 

II

18 (9%)

98 (48%)

87 (43%)

 

III

11 (15%)

28 (40%)

32 (45%)

 

IV

0 (0%)

5 (33%)

10 (67%)

 

Tumor Size

   

P = 0.238

T1

56 (14%)

185 (45%)

171 (41%)

 

T2

11 (8%)

66 (45%)

69 (47%)

 

T3

7 (18%)

17 (45%)

14 (37%)

 

Grade

   

P = 0.852

1

25 (13%)

83 (42%)

88 (45%)

 

2

30 (13%)

104 (46%)

95 (41%)

 

3

18 (10%)

77 (44%)

79 (46%)

 

Hormone Statusa

   

P = 0.583

ER + PR+

54 (14%)

165 (43%)

162 (43%)

 

ER + PR-

10 (11%)

46 (49%)

37 (40%)

 

ER-PR-

12 (10%)

57 (45%)

56 (45%)

 

HER2 Status

   

P = 0.788

Positive

9 (10%)

38 (44%)

40 (46%)

 

Negative

60 (13%)

201 (43%)

203 (44%)

 

Intrinsic Subtypeb

   

P = 0.748

Luminal A

54 (14%)

169 (44%)

165 (42%)

 

Luminal B

4 (8%)

21 (45%)

22 (47%)

 

HER2 enriched

5 (12%)

17 (43%)

18 (45%)

 

Triple negative

6 (8%)

32 (42%)

38 (50%)

 

Tumor Type

   

P = 0.196

IDCA

41 (10%)

191 (46%)

185 (44%)

 

ILCA

18 (19%)

41 (44%)

35 (37%)

 

Mixed ILCA/IDCA

4 (13%)

12 (40%)

14 (47%)

 

Otherc

8 (18%)

17 (39%)

19 (43%)

 

Lymph Node Statusd

   

P = 0.546

Negative

51 (12%)

181 (44%)

183 (44%)

 

Positive

16 (11%)

74 (48%)

62 (41%)

 

Patient Status

   

P = 0.857

Disease-freee

23 (13%)

85 (49%)

66 (38%)

 

Recurrence

5 (13%)

19 (49%)

15 (38%)

 

Dead of Disease

4 (13%)

12 (39%)

15 (48%)

 
  1. aOnly a single patient had confirmed ER-PR + status, thus this rare tumor type was not included in the analysis.
  2. bIntrinsic subtypes were defined as luminal A = ER and or PR+/HER2-; luminal B = ER and or/PR+/HER2+; HER2-enriched = ER and PR-/HER2+ and triple negative = ER, PR and HER2-.
  3. cOther included histological types including tubular, medullary, apocrine, and mucinous carcinomas.
  4. dPatients with isolated tumor cells (n = 33) were not included in this analysis.
  5. eOnly patients who have been disease-free ≥5 years were included in this analysis.
  6. Data was not available for each variable for every patient thus “N” varies by characteristic.
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us